University of California, San Francisco, Kidney Transplant Service, 505 Parnassus Avenue, M884, San Francisco, CA 94143-0780, USA.
Clin J Am Soc Nephrol. 2010 Jan;5(1):142-51. doi: 10.2215/CJN.04580709. Epub 2009 Dec 10.
B cells and antibodies play an important role in the alloresponse to renal grafts as well as in immune-mediated glomerular diseases. In transplantation, greater recognition and improved diagnosis of antibody-mediated rejection have been a catalyst to the introduction of newer drugs and regimens that target B cells, plasma cells, and donor-specific antibodies to improve the outcome associated with antibody-mediated rejection. In immune-mediated renal disease, novel and more selective B cell therapies are gradually modifying the traditional therapeutic approach that consists of steroids and other immunosuppressants. A new era of selective and more effective immunosuppression agents that target the humoral response is finally emerging in transplantation and renal diseases.
B 细胞和抗体在肾移植的同种异体反应以及免疫介导的肾小球疾病中发挥重要作用。在移植中，对抗体介导排斥反应的更深入认识和更好的诊断，促进了新型药物和方案的引入，这些药物和方案靶向 B 细胞、浆细胞和供体特异性抗体，以改善与抗体介导排斥反应相关的结局。在免疫介导的肾脏疾病中，新型、更具选择性的 B 细胞疗法逐渐改变了传统的治疗方法，该方法由类固醇和其他免疫抑制剂组成。在移植和肾脏疾病中，一种针对体液反应的新型、更有效的选择性免疫抑制剂终于崭露头角。
